Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Molecular Bacterial Load Assay Concurs with Culture on NaOH-Induced Loss of Mycobacterium tuberculosis Viability.

Mtafya B, Sabiiti W, Sabi I, John J, Sichone E, Ntinginya NE, Gillespie SH.

J Clin Microbiol. 2019 Jun 25;57(7). pii: e01992-18. doi: 10.1128/JCM.01992-18. Print 2019 Jul.

PMID:
31018981
2.

Phenotypic Changes on Mycobacterium Tuberculosis-Specific CD4 T Cells as Surrogate Markers for Tuberculosis Treatment Efficacy.

Ahmed MIM, Ntinginya NE, Kibiki G, Mtafya BA, Semvua H, Mpagama S, Mtabho C, Saathoff E, Held K, Loose R, Kroidl I, Chachage M, von Both U, Haule A, Mekota AM, Boeree MJ, Gillespie SH, Hoelscher M, Heinrich N, Geldmacher C.

Front Immunol. 2018 Sep 28;9:2247. doi: 10.3389/fimmu.2018.02247. eCollection 2018.

3.

The impact of repeated NALC/NaOH- decontamination on the performance of Xpert MTB/RIF assay.

Rachow A, Saathoff E, Mtafya B, Mapamba D, Mangu C, Rojas-Ponce G, Ntinginya NE, Boeree M, Heinrich N, Gillespie SH, Hoelscher M; PanACEA-Consortium.

Tuberculosis (Edinb). 2018 May;110:56-58. doi: 10.1016/j.tube.2018.04.001. Epub 2018 Apr 5.

PMID:
29779774
4.

Why being an expert - despite xpert -remains crucial for children in high TB burden settings.

Bacha JM, Ngo K, Clowes P, Draper HR, Ntinginya EN, DiNardo A, Mangu C, Sabi I, Mtafya B, Mandalakas AM.

BMC Infect Dis. 2017 Feb 6;17(1):123. doi: 10.1186/s12879-017-2236-9.

5.

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.

Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, Sanne I, Ntinginya NE, Minja LT, Hunt RD, Charalambous S, Hanekom M, Semvua HH, Mpagama SG, Manyama C, Mtafya B, Reither K, Wallis RS, Venter A, Narunsky K, Mekota A, Henne S, Colbers A, van Balen GP, Gillespie SH, Phillips PPJ, Hoelscher M; PanACEA consortium.

Lancet Infect Dis. 2017 Jan;17(1):39-49. doi: 10.1016/S1473-3099(16)30274-2. Epub 2016 Oct 26.

6.

Optimising molecular diagnostic capacity for effective control of tuberculosis in high-burden settings.

Sabiiti W, Mtafya B, Kuchaka D, Azam K, Viegas S, Mdolo A, Farmer EC, Khonga M, Evangelopoulos D, Honeyborne I, Rachow A, Heinrich N, Ntinginya NE, Bhatt N, Davies GR, Jani IV, McHugh TD, Kibiki G, Hoelscher M, Gillespie SH; PANBIOME (Pan-African Biomarker Expansion Programme) consortium.

Int J Tuberc Lung Dis. 2016 Aug;20(8):1004-9. doi: 10.5588/ijtld.15.0951.

PMID:
27393531
7.

Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial.

Peter JG, Zijenah LS, Chanda D, Clowes P, Lesosky M, Gina P, Mehta N, Calligaro G, Lombard CJ, Kadzirange G, Bandason T, Chansa A, Liusha N, Mangu C, Mtafya B, Msila H, Rachow A, Hoelscher M, Mwaba P, Theron G, Dheda K.

Lancet. 2016 Mar 19;387(10024):1187-97. doi: 10.1016/S0140-6736(15)01092-2. Epub 2016 Mar 10.

PMID:
26970721
8.

Performance of urine lipoarabinomannan assays for paediatric tuberculosis in Tanzania.

Kroidl I, Clowes P, Reither K, Mtafya B, Rojas-Ponce G, Ntinginya EN, Kalomo M, Minja LT, Kowuor D, Saathoff E, Kroidl A, Heinrich N, Maboko L, Bates M, O'Grady J, Zumla A, Hoelscher M, Rachow A.

Eur Respir J. 2015 Sep;46(3):761-70. doi: 10.1183/09031936.00003315. Epub 2015 Jun 25.

9.

The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations.

Bowness R, Boeree MJ, Aarnoutse R, Dawson R, Diacon A, Mangu C, Heinrich N, Ntinginya NE, Kohlenberg A, Mtafya B, Phillips PP, Rachow A, Plemper van Balen G, Gillespie SH.

J Antimicrob Chemother. 2015 Feb;70(2):448-55. doi: 10.1093/jac/dku415. Epub 2014 Oct 25.

PMID:
25344806
10.

The molecular bacterial load assay replaces solid culture for measuring early bactericidal response to antituberculosis treatment.

Honeyborne I, Mtafya B, Phillips PP, Hoelscher M, Ntinginya EN, Kohlenberg A, Rachow A, Rojas-Ponce G, McHugh TD, Heinrich N; Pan African Consortium for the Evaluation of Anti-tuberculosis Antibiotics.

J Clin Microbiol. 2014 Aug;52(8):3064-7. doi: 10.1128/JCM.01128-14. Epub 2014 May 28.

11.

Performance of the Xpert® MTB/RIF assay in an active case-finding strategy: a pilot study from Tanzania.

Ntinginya EN, Squire SB, Millington KA, Mtafya B, Saathoff E, Heinrich N, Rojas-Ponce G, Kowuor D, Maboko L, Reither K, Clowes P, Hoelscher M, Rachow A.

Int J Tuberc Lung Dis. 2012 Nov;16(11):1468-70. doi: 10.5588/ijtld.12.0127. Epub 2012 Sep 7.

PMID:
22964006
12.

Increased and expedited case detection by Xpert MTB/RIF assay in childhood tuberculosis: a prospective cohort study.

Rachow A, Clowes P, Saathoff E, Mtafya B, Michael E, Ntinginya EN, Kowour D, Rojas-Ponce G, Kroidl A, Maboko L, Heinrich N, Reither K, Hoelscher M.

Clin Infect Dis. 2012 May;54(10):1388-96. doi: 10.1093/cid/cis190. Epub 2012 Apr 3.

PMID:
22474220
13.

Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay--a clinical validation study.

Rachow A, Zumla A, Heinrich N, Rojas-Ponce G, Mtafya B, Reither K, Ntinginya EN, O'Grady J, Huggett J, Dheda K, Boehme C, Perkins M, Saathoff E, Hoelscher M.

PLoS One. 2011;6(6):e20458. doi: 10.1371/journal.pone.0020458. Epub 2011 Jun 29.

Supplemental Content

Loading ...
Support Center